ACK1 promotes hepatocellular carcinoma progression via downregulating WWOX and activating AKT signaling

Xie,Binhui; Zen,Qinshan; Wang,Xiaonong; He,Xiao; Xie,Yuankang; Zhang,Zixiang; Li,Heping

doi:10.3892/ijo.2015.2910

ACK1 promotes hepatocellular carcinoma progression via downregulating WWOX and activating AKT signaling

Authors:
- Binhui Xie
- Qinshan Zen
- Xiaonong Wang
- Xiao He
- Yuankang Xie
- Zixiang Zhang
- Heping Li
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, P.R. China, Department of Gastroenterology, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, P.R. China, Department of Interventional Radiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, P.R. China
Published online on: February 27, 2015 https://doi.org/10.3892/ijo.2015.2910
Pages: 2057-2066

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several studies have revealed that ACK1 is upregulated in various cancers and promotes tumor progression. However, the role and mechanism of ACK1 in hepatocellular carcinoma (HCC) remains unknown. In this study, the expression of ACK1 was assessed in several cell lines and 150 pairs of HCC and adjacent noncancerous liver tissues. The protein expression of p-ACK1 and WWOX were detected by immunohistochemistry to evaluate their correlation with ACK1. Flow cytometry, caspase 3/7 activity assay, BrdU cell proliferation assay, MTT assay and Transwell assay were used to detect apoptosis, proliferation, invasion and migration of HCC cells. The regulatory effect of ACK1 on WWOX, AKT, p-AKT, MMP2 and MMP9 in HCC cells was confirmed by immunoblotting. We found that ACK1 was more highly expressed in HCC tissues than in non-HCC tissues, and overexpression of ACK1 was correlated with clinicopathological features of poor prognosis. Clinical analysis demonstrated that ACK1 is an independent prognostic marker for predicting overall survival and disease-free survival of HCC patients. Pearson's correlation coefficient analysis indicated that ACK1 was positively associated with p-ACK1 and was negatively associated with WWOX expression. In vitro studies showed that knockdown of ACK1 promoted HCC cell apoptosis and repressed HCC cells invasion, migration and proliferation. Furthermore, knockdown of ACK1 resulted in upregulation of WWOX and inactivation of AKT signaling. In this study, we also found that knockdown of ACK1 resulted in the downregulation of MMP2 and MMP9 in HCC. Our results indicate that ACK1 is an independent prognostic marker and promotes HCC progression via downregulating WWOX and activating AKT signaling.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Chen WQ, Zeng HM, Zheng RS, Zhang SW and He J: Cancer incidence and mortality in China, 2007. Chin J Cancer Res. 24:1–8. 2012. View Article : Google Scholar
3	Nishikawa H, Osaki Y, Endo M, et al: Japanese Red Cross Liver Study Group: Comparison of standard-dose and half-dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis. Int J Oncol. 45:2295–2302. 2014.PubMed/NCBI
4	Venook AP, Papandreou C, Furuse J and de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective. Oncologist. 15(Suppl 4): 5–13. 2010. View Article : Google Scholar : PubMed/NCBI
5	Alazawi W, Cunningham M, Dearden J and Foster GR: Systematic review: Outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 32:344–355. 2010. View Article : Google Scholar : PubMed/NCBI
6	Liu Q, Tu K, Zhang H, Zheng X, Yao Y and Liu Q: TPX2 as a novel prognostic biomarker for hepatocellular carcinoma. Hepatol Res. Sep 29–2014.(Epub ahead of print). View Article : Google Scholar
7	Bruix J and Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
8	Han S, Han L, Yao Y, Sun H, Zan X and Liu Q: Activated hepatic stellate cells promote hepatocellular carcinoma cell migration and invasion via the activation of FAK-MMP9 signaling. Oncol Rep. 31:641–648. 2014.
9	Nur-E-Kamal MS, Kamal JM, Qureshi MM and Maruta H: The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation. Oncogene. 18:7787–7793. 1999. View Article : Google Scholar
10	Prieto-Echagüe V, Gucwa A, Craddock BP, Brown DA and Miller WT: Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1. J Biol Chem. 285:10605–10615. 2010. View Article : Google Scholar : PubMed/NCBI
11	Chan W, Tian R, Lee YF, Sit ST, Lim L and Manser E: Down-regulation of active ACK1 is mediated by association with the E3 ubiquitin ligase Nedd4–2. J Biol Chem. 284:8185–8194. 2009. View Article : Google Scholar : PubMed/NCBI
12	Grøvdal LM, Johannessen LE, Rødland MS, Madshus IH and Stang E: Dysregulation of Ack1 inhibits down-regulation of the EGF receptor. Exp Cell Res. 314:1292–1300. 2008. View Article : Google Scholar : PubMed/NCBI
13	Kelley LC and Weed SA: Cortactin is a substrate of activated Cdc42-associated kinase 1 (ACK1) during ligand-induced epidermal growth factor receptor downregulation. PLoS One. 7:e443632012. View Article : Google Scholar : PubMed/NCBI
14	Gajiwala KS, Maegley K, Ferre R, He YA and Yu X: Ack1: Activation and regulation by allostery. PLoS One. 8:e539942013. View Article : Google Scholar : PubMed/NCBI
15	Shinmura K, Kiyose S, Nagura K, Igarashi H, Inoue Y, Nakamura S, Maeda M, Baba M, Konno H and Sugimura H: TNK2 gene amplification is a novel predictor of a poor prognosis in patients with gastric cancer. J Surg Oncol. 109:189–197. 2014. View Article : Google Scholar
16	Howlin J, Rosenkvist J and Andersson T: TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells. Breast Cancer Res. 10:R362008. View Article : Google Scholar : PubMed/NCBI
17	Mahajan K, Coppola D, Challa S, et al: Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One. 5:e96462010. View Article : Google Scholar : PubMed/NCBI
18	Mahajan K and Mahajan NP: ACK1 tyrosine kinase: Targeted inhibition to block cancer cell proliferation. Cancer Lett. 338:185–192. 2013. View Article : Google Scholar : PubMed/NCBI
19	Li YP, Wu CC, Chen WT, Huang YC and Chai CY: The expression and significance of WWOX and β-catenin in hepatocellular carcinoma. APMIS. 121:120–126. 2013. View Article : Google Scholar
20	Salah Z, Aqeilan R and Huebner K: WWOX gene and gene product: Tumor suppression through specific protein interactions. Future Oncol. 6:249–259. 2010. View Article : Google Scholar : PubMed/NCBI
21	Yang J and Zhang W: WWOX tumor suppressor gene. Histol Histopathol. 23:877–882. 2008.PubMed/NCBI
22	Lewandowska U, Zelazowski M, Seta K, Byczewska M, Pluciennik E and Bednarek AK: WWOX, the tumour suppressor gene affected in multiple cancers. J Physiol Pharmacol. 60(Suppl 1): 47–56. 2009.PubMed/NCBI
23	Mahajan K and Mahajan NP: Shepherding AKT and androgen receptor by Ack1 tyrosine kinase. J Cell Physiol. 224:327–333. 2010. View Article : Google Scholar : PubMed/NCBI
24	Zheng X, Gai X, Ding F, Lu Z, Tu K, Yao Y and Liu Q: Histone acetyltransferase PCAF up-regulated cell apoptosis in hepatocellular carcinoma via acetylating histone H4 and inactivating AKT signaling. Mol Cancer. 12:962013. View Article : Google Scholar : PubMed/NCBI
25	Liu Q, Yang P, Tu K, Zhang H, Zheng X, Yao Y and Liu Q: TPX2 knockdown suppressed hepatocellular carcinoma cell invasion via inactivating AKT signaling and inhibiting MMP2 and MMP9 expression. Chin J Cancer Res. 26:410–417. 2014.PubMed/NCBI
26	Mahajan K and Mahajan NP: PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J Cell Physiol. 227:3178–3184. 2012. View Article : Google Scholar : PubMed/NCBI
27	Tan DS, Haaland B, Gan JM, et al: Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer. Mol Cancer. 13:132014. View Article : Google Scholar : PubMed/NCBI
28	van der Horst EH, Degenhardt YY, Strelow A, et al: Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci USA. 102:15901–15906. 2005. View Article : Google Scholar : PubMed/NCBI
29	Mahajan K, Coppola D, Rawal B, Chen YA, Lawrence HR, Engelman RW, Lawrence NJ and Mahajan NP: Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. J Biol Chem. 287:22112–22122. 2012. View Article : Google Scholar : PubMed/NCBI
30	Chua BT, Lim SJ, Tham SC, Poh WJ and Ullrich A: Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells. Mol Oncol. 4:323–334. 2010. View Article : Google Scholar : PubMed/NCBI
31	Mahajan K, Coppola D, Chen YA, Zhu W, Lawrence HR, Lawrence NJ and Mahajan NP: Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. Am J Pathol. 180:1386–1393. 2012. View Article : Google Scholar : PubMed/NCBI
32	Cheng CH, Lee CF, Wu TH, Chan KM, Chou HS, Wu TJ, Yu MC, Chen TC, Lee WC and Chen MF: Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol. 9:1142011. View Article : Google Scholar : PubMed/NCBI
33	Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Gevariya H, Zhu W, Chen YA, Lawrence NJ and Mahajan NP: Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate. 70:1274–1285. 2010.PubMed/NCBI
34	Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI